| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d16c73833a9ec380ce18fa4a3b5eefb2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2010-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea9941fbf83b9ba3a8e60c63349e44b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e587941a07227f33eb6cad4a8b0605de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e2c82eb7bfc048bb49fd43b27cbffac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f5cb402d0c313e4d3a8ac83fb3a981e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_083c2ec00a12edcb74dd3c0b8cc4e929 |
| publicationDate |
2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-599996-A |
| titleOfInvention |
A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent |
| abstract |
Disclosed is a pharmaceutical composition comprising the protease proenzymes trypsinogen and chymotrypsinogen. The composition may further comprise an active agent is selected from at least one of a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent, and optionally a glycoside hydrolase. The vanilloid compound may be capsiate, namely 4-hydroxy-3-methoxybenzyl-(E)-8-methyl-6-nonenoate, the glycoside hydrolase may be a-amylase and the cytoplasmic glycolysis reduction agent may be 2-deoxy-D-glucose. The disclosure also relates to the use of the composition for the treatment of cancer. |
| priorityDate |
2009-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |